Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4776 - 4800 of 5888 in total
Lonigutamab is under investigation in clinical trial NCT05683496 (Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)).
Investigational
Experimental
Investigational
Investigational
Investigational
PD-169316 is a p38 MAP kinase inhibitor.
Investigational
Butyrfentanyl or butyrylfentanyl (not to be confused with 3-methylfentanyl) is a potent short-acting synthetic opioid analgesic drug. It is an analog of fentanyl with roughly 1/30 the potency. Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. Butyrfentanyl has no current legitimate clinical applications, but...
Illicit
Investigational
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular...
Investigational
Matched Description: … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes. …
Isoliquiritigenin is a precursor to several flavonones in many plants.
Experimental
Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Experimental
Investigational
Investigational
Experimental
Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
Investigational
Experimental
Displaying drugs 4776 - 4800 of 5888 in total